Drugs / Autologous γδT cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04028440 | Oct 2019 → Dec 2020 | chronic lymphocytic leukemia/small lymphocytic lymphoma, peripheral T-cell lymphoma, not otherwise specified | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04032392 | Jul 2019 → Jul 2021 | hepatocellular carcinoma | Beijing 302 Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous γδT cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04028440 ↗ |
| Modality | Cell therapy | “Autologous γδT cells” NCT04028440 ↗ |
| Route | Intravenous | “single infusion intravenously” NCT04028440 ↗ |